Author: plus91

This author has written 287 articles

Abstract Drug-resistant tuberculosis (DR-TB) is a major problem both in India and worldwide. Newer drugs such as TMC-207 (bedaquiline) may have an important role to play in making…

Continue Reading Initial experience of bedaquiline use in a series of drug-resistant tuberculosis patients from India.

Abstract BACKGROUND: There is very limited data on the experience and outcome of multidrug-resistant tuberculosis (MDR-TB) patients treated privately out of the DOTS plus program. Goal of this…

Continue Reading Multidrug-resistant-tuberculosis treatment in the Indian private sector: Results from a tertiary referral private hospital in Mumbai.

Go to Publication

Continue Reading “Chennai Declaration”: 5-year plan to tackle the challenge of anti-microbial resistance.

Abstract BACKGROUND: Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that targets multiple tyrosine kinases. A phase 2 trial suggested that treatment with 150 mg of…

Continue Reading Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.

Abstract Extensively drug-resistant tuberculosis is a burgeoning global health crisis mainly affecting economically active young adults, and has high mortality irrespective of HIV status. In some countries such…

Continue Reading Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis.